Augmedix price target raised to $8 from $5 at Maxim

Maxim raised the firm’s price target on Augmedix (AUGX) to $8 from $5 and keeps a Buy rating on the shares. The company’s partnership with HCA Healthcare (HCA) has the potential to increase its total addressable market by 20% given the latter’s large hospital portfolio, while its capital raise is expected to enable the company to achieve positive cash flow without additional financing, the analyst tells investors in a research note. The stock was up 89% in yesterday’s trading, closing at $3.40.